Pular para o conteúdo
Carcinoma do esôfago
ORPHA:70482DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Início adulta
Também conhecida comoCECECEADE
Sinônimos clínicos: Carcinoma esofágico

O câncer de esôfago (CE) é um tumor que surge nas células que revestem a parte interna do esôfago e pode ser dividido em dois tipos principais: o câncer de células escamosas do esôfago (CECE) e o adenocarcinoma de esôfago (ADE).

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

O carcinoma do esôfago é um tipo de tumor que se forma nas células que revestem o interior do esôfago, canal responsável por levar o alimento da boca até o estômago. A pessoa com a condição pode sentir sintomas como queimação por refluxo gastroesofágico, dor no peito, tosse persistente e náuseas. O diagnóstico é confirmado pela identificação das células tumorais na parede esofágica, podendo envolver subtipos como o adenocarcinoma ou o carcinoma escamoso. No Brasil, a condição não está incluída na lista oficial de PCDTs de doenças raras do SUS, devendo o paciente buscar apoio e acompanhamento pela rede oncológica de saúde.

📋
Informacoes curadas por IA — podem conter imprecisoes

O câncer de esôfago (CE) é um tumor que surge nas células que revestem a parte interna do esôfago e pode ser dividido em dois tipos principais: o câncer de células escamosas do esôfago (CECE) e o adenocarcinoma de esôfago (ADE).

Pesquisas ativas
39 ensaios
107 total registrados no ClinicalTrials.gov
Publicações científicas
286 artigos
Último publicado: 2025 Jul 1

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
7.1
Europe
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
4 sintomas
📏
Crescimento
2 sintomas
🫁
Pulmão
1 sintomas
🦴
Ossos e articulações
1 sintomas
🩸
Sangue
1 sintomas

+ 2 sintomas em outras categorias

Características mais comuns

—
Dificuldades alimentares na infância
—
Dor torácica
—
Anormalidade da voz
—
Tosse
—
Esôfago de Barrett
—
Refluxo gastroesofágico
11sintomas
Sem dados (11)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 11 características clínicas mais associadas, ordenadas por frequência.

Dificuldades alimentares na infânciaFeeding difficulties in infancy
Dor torácicaChest pain
Anormalidade da vozAbnormality of the voice
TosseCough
Esôfago de BarrettBarrett esophagus

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico286PubMed
Últimos 10 anos77publicações
Pico202115 papers
Linha do tempo
2025Hoje · 2026🧪 1997Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

5 genes identificados com associação a esta condição.

ERBB2Receptor tyrosine-protein kinase erbB-2Candidate gene tested inRestrito
VIAS BIOLÓGICAS (9)
Signaling by ERBB2Constitutive Signaling by Overexpressed ERBB2Drug-mediated inhibition of ERBB2 signalingDownregulation of ERBB2 signalingSema4D induced cell migration and growth-cone collapse
MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
130.1 TPM
Skin Sun Exposed Lower leg
118.3 TPM
Esôfago - Mucosa
113.1 TPM
Skin Not Sun Exposed Suprapubic
110.9 TPM
Tireoide
99.3 TPM
OUTRAS DOENÇAS (9)
gastric cancervisceral neuropathy, familial, 2, autosomal recessiveglioma susceptibility 1lung cancer
HGNC:3430UniProt:P04626
RNF6E3 ubiquitin-protein ligase RNF6Candidate gene tested inModerado
VIAS BIOLÓGICAS (1)
Antigen processing: Ubiquitination & Proteasome degradation
MECANISMO DE DOENÇA

Esophageal cancer

A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
38.2 TPM
Fibroblastos
35.7 TPM
Testículo
33.9 TPM
Cérebro - Hemisfério cerebelar
31.8 TPM
Cerebelo
24.3 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
esophageal canceresophageal squamous cell carcinoma
HGNC:10069UniProt:Q9Y252
WWOXWW domain-containing oxidoreductaseCandidate gene tested inTolerante
VIAS BIOLÓGICAS (3)
Nuclear signaling by ERBB4Activation of the TFAP2 (AP-2) family of transcription factorsNegative regulation of activity of TFAP2 (AP-2) family transcription factors
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
13.8 TPM
Cérebro - Hemisfério cerebelar
12.1 TPM
Cerebelo
11.2 TPM
Brain Spinal cord cervical c-1
10.5 TPM
Nervo tibial
8.2 TPM
OUTRAS DOENÇAS (5)
autosomal recessive spinocerebellar ataxia 12esophageal cancerdevelopmental and epileptic encephalopathy, 28esophageal squamous cell carcinoma
HGNC:12799UniProt:Q9NZC7
TGFBR2TGF-beta receptor type-2Candidate gene tested inRestrito
VIAS BIOLÓGICAS (8)
TGF-beta receptor signaling activates SMADsDownregulation of TGF-beta receptor signalingUCH proteinasesTGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)TGFBR1 LBD Mutants in Cancer
MECANISMO DE DOENÇA

Hereditary non-polyposis colorectal cancer 6

An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
377.2 TPM
Tecido adiposo
319.8 TPM
Adipose Visceral Omentum
301.0 TPM
Mama
271.8 TPM
Nervo tibial
261.1 TPM
OUTRAS DOENÇAS (7)
Loeys-Dietz syndrome 2esophageal cancercolorectal cancer, hereditary nonpolyposis, type 6familial thoracic aortic aneurysm and aortic dissection
HGNC:11773UniProt:P37173
DLEC1Deleted in lung and esophageal cancer protein 1Candidate gene tested inTolerante
EXPRESSÃO TECIDUAL(Tecido-específico)
Testículo
42.5 TPM
Pituitária
23.6 TPM
Fallopian Tube
15.6 TPM
Pulmão
5.4 TPM
Nervo tibial
3.8 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (1)
esophageal squamous cell carcinoma
HGNC:2899UniProt:Q9Y238

Variantes genéticas (ClinVar)

991 variantes patogênicas registradas no ClinVar.

🧬 DLEC1: GRCh37/hg19 3p26.3-14.3(chr3:2263690-55016039)x3 ()
🧬 DLEC1: NM_007335.4(DLEC1):c.3914A>G (p.Glu1305Gly) ()
🧬 DLEC1: NM_007335.4(DLEC1):c.1797T>A (p.Ser599=) ()
🧬 DLEC1: NM_007335.4(DLEC1):c.1666-3C>G ()
🧬 DLEC1: NM_007335.4(DLEC1):c.1261+97A>G ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 4 variantes classificadas pelo ClinVar.

2
1
1
Patogênica (50.0%)
VUS (25.0%)
Benigna (25.0%)
VARIANTES MAIS SIGNIFICATIVAS
MSR1: NM_138715.3:c.688_1356del [Likely pathogenic]
MSR1: NM_138715.3(MSR1):c.31C>T (p.Gln11Ter) [Likely pathogenic]
MSR1: NM_138715.3(MSR1):c.-4-1G>A [Uncertain significance]
BRCA2: NM_000059.4(BRCA2):c.3445A>G (p.Met1149Val) [Benign/Likely benign]

Vias biológicas (Reactome)

44 vias biológicas associadas aos genes desta condição.

Signaling by ERBB2 SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Antigen processing: Ubiquitination & Proteasome degradation Nuclear signaling by ERBB4 Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 MSI Frameshift Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer UCH proteinases TGFBR3 regulates TGF-beta signaling

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Carcinoma do esôfago

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 10 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

26 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07594626 · BMS-986504 in Combination With Pemetrexed for the Treatment …Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07795749 · Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07596654 · The Impact of Surgical Treatment on Survival in Localized Sm…Recrutando
🇨🇳 China
NCT07000253 · Timing of Comprehensive Local Treatment After First-Line Sys…Recrutando
PHASE2🇳🇱 Países Baixos · 🇳🇴 Noruega · 🇪🇸 Espanha
NCT07283939 · Studying the PAGODA Algorithm for Chemotherapy Dose Changes …Recrutando
NAGuam · Puerto Rico · 🇺🇸 Estados Unidos
NCT07108855 · Detection of Upper Gastrointestinal Tumour Depth and Demarca…Recrutando
PHASE1, PHASE2🇳🇱 Países Baixos
NCT06872515 · Impact of Prehabilitation in Oncology Via Exercise- Esophage…Recrutando
NA🇺🇸 Estados Unidos
NCT06995898 · The Vanguard Study: Testing a New Way to Screen for CancerRecrutando
NA🇺🇸 Estados Unidos
NCT06964568 · CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Local…Recrutando
PHASE3🇨🇳 China
NCT06414733 · HER-2 B Cell Peptide VaccineRecrutando
PHASE1🇺🇸 Estados Unidos
NCT06645808 · PET-imaging of Two Vartumabs in Patients With Solid TumorsRecrutando
EARLY_PHASE1🇳🇱 Países Baixos
NCT06676449 · TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Local…Recrutando
PHASE3🇨🇳 China
NCT05705492 · Olanzapine for the Management of Cancer Associated Appetite …Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06067438 · Amiodarone for the Prevention of Atrial Fibrillation After M…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06354218 · Serplulimab Combined With Concurrent Chemoradiotherapy for L…Recrutando
PHASE2🇨🇳 China
NCT06199895 · Clinical Efficacy and Safety of Paclitaxel Polymeric Micelle…Recrutando
PHASE2🇨🇳 China
NCT05937438 · Postoperative Radiotherapy Followed by Immunotherapy for Loc…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT05952661 · Minimally Residual of Esophageal Cancer 001Recrutando
🇨🇳 China
NCT05775939 · PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patie…Recrutando
NA🇺🇸 Estados Unidos
NCT05357846 · PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy P…Recrutando
PHASE3🇨🇳 China
NCT05059444 · ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Ev…Recrutando
🇫🇷 França · 🇩🇪 Alemanha · 🇮🇹 Itália +2
NCT07309991 · Postoperative Hypoxemia Increases the Risk of Anastomotic Le…Recrutando
🇨🇳 China
NCT04652180 · Robot-assisted Thoracic Approach Versus Open Transthoracic E…Recrutando
NA🇪🇸 Espanha
NCT03948100 · Dyadic Yoga Intervention in Improving Physical Performance a…Recrutando
NA🇺🇸 Estados Unidos
NCT00991094 · Data Collection for the Assessment of Acute and Late Normal …Recrutando
🇺🇸 Estados Unidos
NCT06990178 · Adaptive Neoadjuvant Therapy for Esophageal CancerPor convite
NA🇨🇳 China

Outros ensaios clínicos

107 ensaios clínicos encontrados, 39 ativos.

Distribuição por fase
NCT06933966 · Evaluation of Efficacy and Safety De-escalation Versus Stand…Em breve
PHASE2🇫🇷 França
NCT07034118 · Definitive Proton Radiotherapy Combined With Chemotherapy an…Em breve
PHASE1🇨🇳 China
NCT06745193 · A Prospective, Randomized, Open, Phase II Clinical Study of …Em breve
PHASE2🇨🇳 China
NCT06681285 · Cadonilimab Combined With Anlotinib Followed by Radiotherapy…Em breve
PHASE2🇨🇳 China
NCT05759325 · An Exploratory Study of ctDNA-MRD in Predicting the Efficacy…Em breve
NCT06914687 · Efficacy of Tirellizumab Combined With Oral, Intravenous and…Ativo
PHASE2🇨🇳 China
NCT06251973 · A Study of agenT-797 in Combination With Botensilimab, Balst…Ativo
PHASE2🇺🇸 Estados Unidos
NCT04147494 · Experimental PET Imaging Scans Before Cancer Surgery to Stud…Ativo
EARLY_PHASE1🇺🇸 Estados Unidos
NCT04607590 · Yoga Program for Improving the Quality of Life in Couples Co…Ativo
NA🇺🇸 Estados Unidos
NCT03110926 · Induction Chemotherapy for Locally Advanced Esophageal Cance…Ativo
PHASE2🇺🇸 Estados Unidos
NCT06828718 · The Neoadjuvant Treatment Modalities in Patients With Locall…Ativo
🇨🇳 China
NCT01366144 · Veliparib, Paclitaxel, and Carboplatin in Treating Patients …Ativo
PHASE1🇺🇸 Estados Unidos
NCT01142388 · Paclitaxel With or Without Cixutumumab as Second-Line Therap…Ativo
PHASE2🇺🇸 Estados Unidos
NCT06712706 · Effect of Feeding Jejunostomy on Sarcopenia in Patients With…Concluído
🇨🇭 Suíça
NCT05795595 · A Safety and Efficacy Study Evaluating CTX131 in Adult Subje…Concluído
PHASE1🇺🇸 Estados Unidos
NCT07460596 · Concentrated Complex Plant Dietary Elements for Chemotherapy…Concluído
PHASE2🇨🇳 China
NCT04505553 · Oral Cryotherapy Plus Acupressure and Acupuncture Versus Ora…Concluído
PHASE2🇺🇸 Estados Unidos
NCT07182266 · Perioperative Outcomes and Survival of Inflatable Video-Assi…Concluído
🇨🇳 China
NCT06048913 · Nimotuzumab Combined With Concurrent Chemoradiotherapy for L…Concluído
PHASE2🇨🇳 China
NCT03819088 · Effects on Quality of Life With Zinc Supplementation in Pati…Concluído
NA🇺🇸 Estados Unidos
NCT04196075 · The Effect of Andrographis Paniculata (AP) on Palliative Man…Concluído
PHASE3🇨🇳 China
NCT03381651 · Different Radiation Dose of Neoadjuvant Chemoradiation for R…Concluído
NA🇨🇳 China
NCT03008278 · Olaparib and Ramucirumab in Treating Patients With Metastati…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03196232 · Epacadostat and Pembrolizumab in Treating Patients With Meta…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03099382 · Study of SHR-1210 Versus Investigator's Choice of Chemothera…Concluído
PHASE3🇨🇳 China
NCT02965976 · Botulinum Toxin Type A in Preventing Complications After Sur…Concluído
PHASE2🇺🇸 Estados Unidos
NCT03933449 · Study of Pembrolizumab (MK-3475) Versus Investigator's Choic…Concluído
PHASE3🇨🇳 China
NCT02559687 · Study of Pembrolizumab (MK-3475) in Previously-Treated Parti…Concluído
PHASE2
NCT02564263 · Study of Pembrolizumab (MK-3475) Versus Investigator's Choic…Concluído
PHASE3
NCT02120911 · Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzu…Concluído
PHASE1, PHASE2🇳🇱 Países Baixos
NCT01855854 · Second-line Treatment With Icotinib in Esophageal Carcinoma …Concluído
PHASE2🇨🇳 China
NCT01691625 · Concurrent Chemoradiation With or Without DC-CIK Immunothera…Concluído
NA🇨🇳 China
NCT01544790 · Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Ope…Concluído
PHASE3🇳🇱 Países Baixos
NCT02023593 · FOLFIRI as Second Line Chemotherapy for Metastatic Esophagea…Concluído
PHASE2🇨🇳 China
NCT01262040 · Narrow Band Imaging (NBI): A Novel Imaging Modality in Minim…Concluído
NA🇺🇸 Estados Unidos
NCT01097304 · Ursodiol in Treating Patients With Barrett Esophagus and Low…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02861690 · Liposomal Paclitaxel Combined Nedaplatin in Treatment of Adv…Concluído
PHASE2🇨🇳 China
NCT01766986 · Staging and Outcome Depending on Surgical Treatment in Adeno…Concluído
NCT00733889 · A Study to Evaluate the Combination of Cetuximab and Chemoth…Concluído
PHASE2🇪🇸 Espanha
NCT00165490 · Combination Chemotherapy, Radiation Therapy and Surgery for …Concluído
PHASE2🇺🇸 Estados Unidos
NCT01269970 · Early Metabolic Response in Locally Advanced Esophageal Canc…Concluído
🇧🇪 Bélgica
NCT00590031 · Phase II Trial of Preoperative Combined Modality Therapy for…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00176800 · Chemoradiation and Tetrathiomolybdate (TM) in Patients With …Concluído
PHASE2🇺🇸 Estados Unidos
NCT01225523 · Perioperative Vs. Preoperative Chemotherapy With Surgery in …Concluído
PHASE1🇨🇳 China
NCT06231680 · Thalidomide Prevention or Treatment of Camrelizumab-induced …UNKNOWN
PHASE2🇨🇳 China
NCT05996484 · Neoadjuvant Therapy of Anlotinib Combined With Toripalimab a…UNKNOWN
PHASE2
NCT06009705 · Toripalimab Combined With Radiotherapy and S-1 for Older Pat…UNKNOWN
🇨🇳 China
NCT06393140 · The Study on the Mechanism of Radiotherapy-elicited Immune R…UNKNOWN
🇨🇳 China
NCT05424432 · Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab…UNKNOWN
PHASE2🇨🇳 China
NCT05208775 · A Comparative Study of Endoscopic Submucosal Dissection and …UNKNOWN
NA
NCT05476380 · Neoadjuvant Therapy of Camrelizumab Combined With Chemothera…UNKNOWN
PHASE2🇨🇳 China
NCT05777707 · Neoadjuvant Therapy of PD-1 Blockade Combined With Chemother…UNKNOWN
PHASE1, PHASE2🇨🇳 China
NCT04517019 · Randomised Trial Evaluating the Benefit of a Fitness Tracker…UNKNOWN
NA🇩🇪 Alemanha
NCT03811379 · Toripalimab as Monotherapy for Patients With Small Cell Carc…UNKNOWN
PHASE2🇨🇳 China
NCT03094351 · Robot-assisted Esophagectomy Versus Conventional Thoracoscop…UNKNOWN
PHASE3🇨🇳 China
NCT03507998 · Phase 1 Dose Escalation Study of CGX1321 in Subjects With Ad…UNKNOWN
PHASE1🇨🇳 China
NCT03013712 · A Clinical Research of CAR T Cells Targeting EpCAM Positive …UNKNOWN
PHASE1, PHASE2🇨🇳 China
NCT02353936 · A Phase II Trial of Afatinib in Patients With Metastatic or …UNKNOWN
PHASE2South Korea
NCT02527057 · Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for E…UNKNOWN
🇨🇳 China
NCT02355249 · Traditional Three Incisions vs Minimally Invasive Thoracol-l…UNKNOWN
PHASE3🇨🇳 China
NCT02072720 · Angiogenic Factor Expression During Fractionated IrradiationUNKNOWN
EARLY_PHASE1🇳🇱 Países Baixos
NCT01937208 · Comparable Study of Different Radiation Dose in Esophageal C…UNKNOWN
PHASE3🇨🇳 China
NCT01486992 · mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy f…UNKNOWN
PHASE2🇨🇳 China
NCT02188615 · Study of Neo-adjuvant Chemoradiotherapy Followed by Minimall…UNKNOWN
PHASE2🇨🇳 China
NCT01034683 · Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Tr…UNKNOWN
PHASE3🇨🇳 China
NCT01044420 · mFOLFIRI as the Second Line Chemotherapy for Advanced Esopha…UNKNOWN
PHASE2🇨🇳 China
NCT00642239 · A Clinical Trial of a Radiation Sensitizer in Radiochemother…UNKNOWN
PHASE4🇨🇳 China
NCT01216527 · Phase III Study of Neo-adjuvant Chemoradiotherapy Followed b…UNKNOWN
PHASE3🇨🇳 China
NCT04929015 · Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment …SUSPENDED
NA🇺🇸 Estados Unidos
NCT06549413 · 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Trea…Encerrado
🇺🇸 Estados Unidos
NCT05780736 · A Study to Evaluate Nivolumab in the Treatment of Early Stag…Encerrado
🇩🇪 Alemanha · 🇺🇸 Estados Unidos
NCT02757391 · CD8+ T Cell Therapy and Pembrolizumab in Treating Patients W…Encerrado
PHASE1🇺🇸 Estados Unidos
NCT03281369 · A Study of Multiple Immunotherapy-Based Treatment Combinatio…Encerrado
PHASE1, PHASE2🇦🇺 Austrália · 🇮🇱 Israel · South Korea +4
NCT02062632 · Doxepin Hydrochloride in Treating Esophageal Pain in Patient…Encerrado
PHASE2🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
77 papers (10 anos)
#1

Neuroendocrine carcinoma of esophagus: systematic review and meta-analysis of case series.

BMC gastroenterology2025 Jul 01

Neuroendocrine carcinoma of the esophagus is a highly aggressive and rare type of cancer, making diagnosis and treatment challenging for clinicians. The current guidelines provide conflicting recommendations, and no standardized treatment protocol is available. We aim to deliver a systematic review of esophageal neuroendocrine carcinoma, including patient characteristics, treatment options, and prognostic factors. PubMed, Web of Science, Scopus, and Embase were searched up to May 2025 to retrieve the relevant studies containing at least 5 cases that reported treatment details, survival outcomes, or patient characteristics. Meta-analysis was conducted using a random-effects model for prognostic factors reported in at least three studies. We calculated survival information using the Kaplan-Meier method and estimated the median 1, 3, and 5-year survival rates in studies with available individual data that did not directly report the survival outcomes. Overall, 24 articles with 1618 cases were included. The median overall survival of patients was 22.5 months, with median 1-, 3-, and 5-year survival rates of 76%, 47%, and 34%, respectively. Distant metastasis (HR, 2.68; 95% CI: 2.10 to 3.41; P < .01) and lymph node involvement (HR, 1.44; 95% CI: 1.04 to 1.99; P = .02) were significantly associated with poor prognosis. Surgery in selected cases improved the survival outcomes with an HR of 0.36 (95% CI, 0.28 to 0.46; P = < .01). The current study demonstrates that distant metastasis and lymph node involvement are significant predictors of poor prognosis in esophageal neuroendocrine carcinoma. Survival outcomes were comparable between patients with resectable tumors undergoing surgery and those receiving definitive chemoradiotherapy, both of which outperformed chemotherapy alone or no treatment. While adjuvant therapy may improve survival in node-positive cases post-surgery, this evidence remains limited by small sample sizes in existing studies. Further large-scale, prospective studies are needed to validate optimal treatment strategies, particularly the role of multimodal therapy in advanced disease.

#2

Carcinoma of Esophagus.

Journal of gastroenterology and hepatology2025 Aug

Carcinoma of esophagus is one of the most common cancer worldwide, but its epidemiology is changing. Squamous cell carcinoma is declining in the East, but adenocarcinoma is rising in the West, probably related to the pandemic of obesity and changing lifestyle. Screening of esophageal cancer (both endoscopic and nonendoscopic methods) is recommended in patients suffering from long-term acid reflux symptoms associated with high-risk factors and surveillance in patients with Barrett's esophagus. Endoscopy with virtual chromoendoscopy, endoscopic ultrasound, and CT scan is essential for diagnosis and staging of the disease. Endoscopic therapy can be used to treat early diseases. Surgery remains a mainstay treatment. Multimodality treatment strategies involving combinations of chemotherapy, radiotherapy, and more recently immunotherapy and target therapies are gaining momentum.

#3

Calmodulin-Like Protein 5 (CALML5) Expression in Squamous Cell Carcinoma of Esophagus and Oropharynx.

Acta histochemica et cytochemica2025 Apr 26

Squamous cell carcinoma (SCC), a common malignancy affecting the skin, vagina, uterine cervix, anus, larynx, and upper digestive tract, is characterized by significant disruption of cell-cell adhesion in stratified squamous epithelium during tumorigenesis, progression, and metastasis. CALML5, a stratified epithelial-specific protein linked to desmosomal junctions, plays a key role in cell adhesion and is notably downregulated in human papillomavirus (HPV)-associated cervical SCC. Esophageal and pharyngeal cancers, commonly with a squamous cell phenotype, have distinct etiologies: oropharyngeal carcinoma is strongly associated with HPV, whereas esophageal carcinoma is linked to environmental factors such as smoking, alcohol, and diet. To investigate the role of CALML5 in these cancers, we performed immunohistochemical analyses on clinical samples and explored its regulatory mechanisms using in vitro studies with human esophageal SCC cell lines. Our findings revealed that CALML5 expression is suppressed in early-stage esophageal SCC but reactivated at invasive sites in well to moderately differentiated SCC undergoing keratinization. In specialized SCC with sarcomatoid component, CALML5 reactivation occurred alongside aberrant KLF4 expression, highlighting its context-dependent role in tumor progression. Conversely, while HPV-unrelated oropharyngeal SCC exhibited patterns similar to esophageal SCC, HPV-related oropharyngeal SCC consistently showed suppressed CALML5 expression due to impaired KLF4 nuclear translocation. These results suggest that CALML5 functions as a tumor suppressor in HPV-associated cervical SCC but may be reactivated in non-HPV-associated invasive SCC, emphasizing its complex role in SCC pathogenesis and the need for careful interpretation of its expression in clinical contexts.

#4

Demographic analysis of survival trends in squamous cell carcinoma of the upper 1/3 of the esophagus: a population-based study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2025 Jan 07

Esophageal malignancies, constituting 3% of global cancers, pose significant health challenges with poor survival rates. Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AC) are predominant subtypes, with shifting incidences globally. This analysis will focus primarily on the demographics of survival trends for Squamous cell carcinoma of esophagus (SCCE). This retrospective study, utilizing the SEER database, examined demographic factors influencing survival trends in SCC of the upper esophagus. Variables included age, sex, race, income, and rurality. Statistical analyses included chi-square tests and multivariable models, specifically logistic regression and conditional inference tree models. A total of 2821 patients were included in this study. Demographic disparities were evident with race (p < 0.001), age (p = 0.002), and sex (p = 0.048) significantly impacting survival when holding other variables constant, with Non-Hispanic Black individuals exhibiting the greatest odds of mortality compared to other racial groups. Median household income (p = 0.344) and Rural-Urban Continuum (p = 0.100) were not significantly associated with improved survival rates when controlling for other demographics. Our findings align with previous research on sex-based survival disparities and racial variations in SCCE incidence and outcomes. Socioeconomic and biological factors contribute to these disparities, highlighting the need for tailored interventions and equitable healthcare access. Understanding demographic determinants in SCCE survival is crucial for personalized treatment and policy reforms to address disparities. Future research should focus on prospective, diverse cohorts to further elucidate these complex interactions and improve esophageal SCCE management and outcomes.

#5

Management of Carcinoma of Esophagus in Old Patient with Panchagavya Therapy as a Palliative Care-A Case Report.

Journal of pharmacy &amp; bioallied sciences2024 Dec

Esophageal cancer is a male-dominant, aggressive malignancy with a five-year survival rate of 15%-20%, predominantly affecting developed nations. Esophageal squamous cell carcinoma (ESCC) is the most common subtype. This case study involves a 70-year-old man with ESCC, who was suffering from difficulty swallowing, inability to burp, constant nausea, and occasional trouble swallowing water for two months. He was successfully treated with Panchagavya Chikitsa, which included Panchagavya Ghrita, Gomutra Arka, Kwath of Amla-Yashtimadhu-Shatpushpa, Haritaki Churna, Haridra Ghanvati, and Vibhitaki Avaleha, along with Nasya, Nabhipurana with Panchagavya Ghrita, and Matra Vasti with Tila Taila over six months. Significant symptom improvement was observed, attributed to the Rasayana (rejuvenative), Balya (strengthening), and Jeevaniya (vitality-enhancing) properties of the treatments. These properties inhibit cancer growth, nourish tissues, and restore balance due to their antioxidant effects. Panchagavya formulations showed promising results without adverse effects, highlighting their efficacy in improving the quality of life for this geriatric patient with ESCC.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC170 artigos no totalmostrando 74

2025

Neuroendocrine carcinoma of esophagus: systematic review and meta-analysis of case series.

BMC gastroenterology
2025

Calmodulin-Like Protein 5 (CALML5) Expression in Squamous Cell Carcinoma of Esophagus and Oropharynx.

Acta histochemica et cytochemica
2024

Management of Carcinoma of Esophagus in Old Patient with Panchagavya Therapy as a Palliative Care-A Case Report.

Journal of pharmacy &amp; bioallied sciences
2025

Demographic analysis of survival trends in squamous cell carcinoma of the upper 1/3 of the esophagus: a population-based study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2024

A case report of metastatic esophageal squamous cell carcinoma during pregnancy.

SAGE open medical case reports
2024

Spatiotemporal Distribution, Time to Treatment Outcome Clustering and Determinants of Esophageal Cancer in Ethiopia, a Scoping Study.

Cancer control : journal of the Moffitt Cancer Center
2024

Adenoid Cystic Carcinoma of Esophagus with Lung Metastasis: Case Report.

Annali italiani di chirurgia
2023

Dosimetric comparison of 3DCRT and IMRT in radical chemoradiotherapy of squamous cell carcinoma esophagus.

Journal of cancer research and therapeutics
2023

Small Cell Oesophageal Carcinoma: A Retrospective Case Series From a UK Tertiary Centre and a Review of the Literature.

Cureus
2023

The role of surgery or definitive chemoradiotherapy in management of localized squamous cell carcinoma of esophagus - What is the verdict?

Critical reviews in oncology/hematology
2024

Undifferentiated Carcinoma of Esophagus with SMARCA4 Deletion Expressing Synaptophysin: A Potential Diagnostic Pitfall.

International journal of surgical pathology
2023

Distal-continual colon interposition for esophageal reconstruction after esophagectomy: Two case reports.

Frontiers in surgery
2023

Corrosive induced early carcinoma of esophagus after 55 years: Resection by endoscopic submucosal dissection.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2022

Neuroendocrine Carcinoma of the Esophagus With Liver Metastasis: A Case Report.

Cureus
2023

Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction.

Journal of surgical oncology
2022

Prevalence, Distribution, and Histopathological Features of Malignant Tumors Reported at Tertiary Level in Afghanistan: A 3-Year Study.

Cancer management and research
2022

[Analysis of Clinicopathological Characteristics of 88 Cases with Secondary Neoplasms of the Thyroid Gland].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
2022

Large-Cell Esophageal Neuroendocrine Tumor Leading to Hepatorenal Syndrome.

Cureus
2022

Esophageal Neuroendocrine Carcinoma: A Case Report and Literature Review.

Cureus
2022

Deleterious mutations in esophageal carcinoma cuniculatum detected by next generation sequencing.

International journal of clinical and experimental pathology
2021

A Rare Case of Primary Small Cell Carcinoma of Esophagus.

Cureus
2021

Expression of CD44 and CD133 stem cell markers in squamous cell carcinoma of esophagus.

Indian journal of pathology &amp; microbiology
2021

Prognostic Significance of the Microbiome and Stromal Cells Phenotype in Esophagus Squamous Cell Carcinoma.

Biomedicines
2021

Association between oral microflora and gastrointestinal tumors (Review).

Oncology reports
2021

A rare case of lung abscess due to esophageo-pulmonary fistula in asymptomatic carcinoma of esophagus.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
2021

Esophageal leiomyoma and simultaneous overlying squamous cell carcinoma: a case report and review of the literature.

BMC surgery
2021

Comparison of treatment response assessed by 18F-FDG PET/CT with the histopathological response using tumor regression grading on surgically resected specimen following neoadjuvant chemotherapy in squamous cell carcinoma of esophagus.

Nuclear medicine communications
2021

A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus.

Scientific reports
2021

The First Literature Case Report: Synchronous Squamous Cell Carcinoma of Esophagus and Adenocarcinoma of Gallbladder.

Journal of gastrointestinal cancer
2021

Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.

Journal of surgical oncology
2021

Nomogram based on nutritional and inflammatory indicators for survival prediction of small cell carcinoma of the esophagus.

Nutrition (Burbank, Los Angeles County, Calif.)
2020

Fungal profile and antifungal susceptibility pattern of candidiasis in esophageal cancer patients.

Journal of cancer research and therapeutics
2020

Modified reverse-puncture anastomotic technique vs. traditional technique for total minimally invasive Ivor-Lewis esophagectomy.

World journal of surgical oncology
2020

Persistent cough: An unexpected diagnosis.

Journal of family medicine and primary care
2020

[A Case of Small Cell Carcinoma of Esophagus in Which Long-Term Survival Was Achieved with Multimodal Treatment].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2021

Plummer-Vinson syndrome: A decade's experience of 132 cases from a single center.

Journal of gastroenterology and hepatology
2020

Clinical profile of patients presenting with dysphagia - an experience from a tertiary care center in North India.

JGH open : an open access journal of gastroenterology and hepatology
2020

Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction.

Annals of surgical oncology
2020

Long-term treatment results and prognostic factors of synchronous and metachronous squamous cell carcinoma of head and neck and esophagus.

Translational cancer research
2021

Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.

Annals of surgery
2019

Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study.

Radiation oncology (London, England)
2019

Gastric Conduit Perforation: A Late Fatal Complication after Esophagectomy.

Cureus
2019

UGT2B17 and miR-224 contribute to hormone dependency trends in adenocarcinoma and squamous cell carcinoma of esophagus.

Bioscience reports
2018

[Neoendocrine carcinoma of the esophagus: report of a case].

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
2019

Expression and Significance of TRIM 28 in Squamous Carcinoma of Esophagus.

Pathology oncology research : POR
2018

Considering the downregulation of Tpm1.6 and Tpm1.7 in squamous cell carcinoma of esophagus as a potent biomarker.

Personalized medicine
2018

Expression and significance of ASPP2 in squamous carcinoma of esophagus.

The Kaohsiung journal of medical sciences
2018

Endoscopic resection with adjuvant chemo-radiotherapy for superficial esophageal squamous cell carcinoma: A critical review.

Critical reviews in oncology/hematology
2017

Endoscopic submucosal dissection in a patient with esophageal adenoid cystic carcinoma.

World journal of gastroenterology
2017

Pneumatic Balloon Dilatation for Achalasia Cardia; Early & late results, a single center study.

Pakistan journal of medical sciences
2018

The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus.

Journal of the Chinese Medical Association : JCMA
2017

Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
2017

Endoscopic diagnosis and management of early squamous cell carcinoma of esophagus.

Journal of thoracic disease
2017

Corrosive-Induced Carcinoma of Esophagus: Esophagographic and CT Findings.

AJR. American journal of roentgenology
2017

SOX2 and Rb1 in esophageal small-cell carcinoma: their possible involvement in pathogenesis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2016

Multiple Meningocerebral Metastasis and Extensive Skull Metastasis from Squamous Cell Carcinoma of Esophagus: A Case Report and Review of Literature.

Brain tumor research and treatment
2017

Robotic-assisted minimally invasive esophagectomy for treatment of esophageal carcinoma.

Journal of robotic surgery
2016

Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy: A case report.

Oncology letters
2016

Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients: A Retrospective Cohort Study of Multicenter Clinical Outcomes.

Medicine
2017

Incidence of esophageal cancer in Sri Lanka: Analysis of cancer registry data and comparison with other South Asian populations.

Asia-Pacific journal of clinical oncology
2015

Squamous cell and neuroendocrine carcinoma of esophagus: Collision versus composite tumor: A case report and review of literature.

Indian journal of cancer
2016

MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
2015

Mucoepidermoid carcinoma of esophagus combined with squamous carcinoma of lung: A case report and literature review.

Journal of cancer research and therapeutics
2016

Genotypes of CYP1A1, SULT1A1 and SULT1A2 and risk of squamous cell carcinoma of esophagus: outcome of a case-control study from Kashmir, India.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
2015

Adenocarcinoma of Cervical Esophagus Arising in the Barrett's Mucosa.

Indian journal of surgical oncology
2015

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus: A Phase III Randomized Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2015

Leu432Val Polymorphism of CYP1B1 is Not Associated with Squamous Cell Carcinoma of Esophagus--a Case-Control Study from Kashmir, India.

Asian Pacific journal of cancer prevention : APJCP
2015

Primary Small Cell Carcinoma of The Esophagus - An Eight Year Retrospective Study.

Journal of clinical and diagnostic research : JCDR
2015

Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus.

Diagnostic pathology
2015

Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy.

Tumori
2015

Oral manifestations of plummer-vinson syndrome: a classic report with literature review.

Journal of international oral health : JIOH
2015

Palliative radiotherapy in esophageal cancer.

The Indian journal of surgery
2015

[Clinicopathologic observation of adenoid cystic carcinoma of esophagus].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2015

Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine.

International journal of oncology
Ver todos os 170 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Carcinoma do esôfago.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Carcinoma do esôfago e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

É um tumor maligno que afeta as células da camada interna do esôfago. Pode se dividir principalmente em câncer de células escamosas (CECE) e adenocarcinoma de esôfago (ADE).

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

5 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. Carcinoma of Esophagus.
    Journal of gastroenterology and hepatology2025PMID 40555648
  2. Demographic analysis of survival trends in squamous cell carcinoma of the upper 1/3 of the esophagus: a population-based study.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2025PMID 39656670
  3. ORPHA:70482
    Orphanet
  4. GARD:6383
    GARD (NIH)
  5. Q18553999
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Carcinoma do esôfago. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/carcinoma-do-esofago

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Carcinoma do esôfago

ORPHA:70482 · MONDO:0019086
Prevalência
1-9 / 100 000
Ensaios
39 ativos
Início
Adult
Prevalência
7.1 (Europe)
MedGen
UMLS
C0152018
EuropePMC
Wikidata
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Dado público estruturado
fonte: Wikidata
Rara